多烯磷脂酰胆碱胶囊联合复方甘草酸苷治疗非酒精性脂肪肝的临床效果

摘要/Abstract

摘要： 目的观察非酒精性脂肪肝治疗中多烯磷脂酰胆碱胶囊与复方甘草酸苷联合应用的临床效果。方法以2017年12月~2021年12月中国人民解放军联勤保障部队第九四一医院收治的60例非酒精性脂肪肝患者为研究对象,将其按照随机数表法分成对照组与观察组,每组30例。对照组采用多烯磷脂酰胆碱胶囊治疗,观察组除应用多烯磷脂酰胆碱胶囊外,加用复方甘草酸苷治疗,观察两组治疗效果。结果观察组治疗有效率高于对照组（P<0.05）。治疗前,两组天门冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）、总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）指标比较,差异无统计学意义（P>0.05）;治疗后,观察组HDL-C高于对照组,AST、ALT、TC、TG、LDL-C低于对照组,差异有统计学意义（P<0.05）。两组治疗期间不良反应发生率比较,差异无统计学意义（P>0.05）。结论临床治疗非酒精性脂肪肝患者时,在多烯磷脂酰胆碱胶囊基础上加用复方甘草酸苷,可提高治疗效果,且患者肝功能、血脂指标均得到有效改善,利于疾病康复,同时患者用药后较少发生不良反应,安全性较高。

关键词: 非酒精性脂肪肝, 多烯磷脂酰胆碱胶囊, 复方甘草酸苷

Abstract: Objective To observe the clinical outcome of polyene phosphatidyl choline capsules combing compound glycyrrhizin in the treatment of non-alcoholic fatty liver disease. Methods 60 patients with non-alcoholic fatty liver disease in No. 941 Hospital of PLA Logistic Support Troops from December 2017 to December 2021 were included in current studies. The patients were randomly divided into control group and observation group, and each group contained 30 patients. Patients in control group were treated with polyene phosphatidyl choline capsules while patients in observation group were administrated with polyene phosphatidyl choline capsules together with compound glycyrrhizin. The therapeutic outcome was observed herein. Results There were no remarkable alterations in the incidence of side effects during the treatment as well as aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) before the treatment (P>0.05). After treatment, compared to control group, the total effective rate and HDL-C in observation group were increased, while AST, ALT,TC, TG and LDL-C were decreased significantly (P<0.05). Conclusion Combination of polyene phosphatidyl choline capsules and compound glycyrrhizin in the treatment of non-alcoholic fatty liver disease could remarkable enhance the therapeutic outcome, improve liver function and blood lipids in patients, promote rehabilitation, and reduce side effects, which indicated the potential high safety.

Key words: non-alcoholic fatty liver disease, polyene phosphatidyl choline capsules, compound glycyrrhizin

中图分类号:

R575.5

赵林. 多烯磷脂酰胆碱胶囊联合复方甘草酸苷治疗非酒精性脂肪肝的临床效果[J]. 中华养生保健, 2022, 40(11): 1-3.

ZHAO Lin. Clinical Outcome of Polyene Phosphatidyl Choline Capsules Combining Compound Glycyrrhizin in the Treatment of Non-alcoholic Fatty Liver Disease[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(11): 1-3.

参考文献

[1] Pouwels S, Sakran N, Graham Y, et al.Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss[J]. BMC Endocr Disord,2022, 22(1):63.
[2] 马华. 二甲双胍联合多烯磷脂酰胆碱治疗非酒精性脂肪肝患者的效果[J].中国民康医学,2021,33(21):27-29.
[3] 郭海燕,杨皓然,史会连,等.异甘草酸镁与复方甘草酸苷治疗非酒精性脂肪性肝病的疗效比较[J].实用临床医药杂志,2021,25(16):36-39.
[4] 黄利娟. 还原型谷胱甘肽联合多烯磷脂酰胆碱治疗非酒精性脂肪肝的效果观察[J].临床医学工程,2021,28(2):195-196.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年修订版)[J].中华肝脏病杂志,2010,18(3):167-170.
[6] Hatanaka T, Kakizaki S, Saito N, et al.Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study[J]. Internal medicine (Tokyo, Japan),2021,60(14):1346-1350.
[7] 李强. 复方甘草酸苷联合多烯磷脂酰胆碱治疗酒精性肝病疗效分析[J].福建医药杂志,2020,42(3):112-113.
[8] 王作典. 多烯磷脂酰胆碱辅助治疗非酒精性脂肪肝的效果及对患者肝功能指标的影响[J].海峡药学,2020,32(2):137-138.
[9] 祝丽娟. 清肝消脂方联合复方甘草酸苷对非酒精性脂肪肝(痰湿内阻证)患者肝功能及血脂水平的影响[J].首都食品与医药,2020,27(3):188-189.
[10] 向芳菲,陈彬彬.胆宁片联合多烯磷脂酰胆碱对非酒精性脂肪肝患者肝功能的改善效果观察[J].黑龙江医药,2019,32(3):598-599.
[11] Honda Y, Ozaki A, Iwaki M, et al.Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice[J]. Journal of Pharmacological Sciences 2021,147(2):753-765.
[12] 梁敏仪,沈杰.多烯磷脂酰胆碱在非酒精性脂肪肝中的应用效果及对氧化、抗氧化的影响[J].中国医学创新,2021,18(3):147-150.
[13] 蔡一珊,占婷,田霞,等.酪酸梭菌联合多烯磷脂酰胆碱对非酒精性脂肪肝肝纤维化的疗效观察[J].中国药师,2021,24(10):1853-1856.
[14] 王冬冬. 复方甘草酸苷联合中药汤剂治疗非酒精性脂肪肝的临床效果观察[J].现代诊断与治疗,2019,30(21):3708-3709.
[15] Wang Z, Xu G, Li Z, et al.NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation[J].J Inflamm Res,2022, 15:409-422.
[16] Li M, Luo Q, Tao Y, et al.Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review[J]. Front Pharmacol,2022, 22(12): 806249.
[17] Bakr AF, Shao P, Farag M A.Recent advances in glycyrrhizin metabolism, health benefits, clinical effects and drug delivery systems for efficacy improvement; a comprehensive review[J]. Phytomedicine, 2022, 10(99):153999.
[18] Liang S B, Hou W B, Zheng R X, et al.Compound glycyrrhizin injection for improving liver function in children with acute icteric hepatitis: A systematic review and meta-analysis[J]. Integr Med Res,2022, 11(1):100772.
[19] Jain R, Hussein M A, Pierce S, et al.Oncopreventive and oncotherapeutic potential of licorice triterpenoid compound glycyrrhizin and its derivatives: Molecular insights[J]. Pharmacol Res,2022,21(178):106138.
[20] Bonafé G A, Boschiero M N, Sodré A R, et al.Natural Plant Compounds: Does Caffeine, Dipotassium Glycyrrhizinate, Curcumin, and Euphol Play Roles as Antitumoral Compounds in Glioblastoma Cell Lines[J]. Front Neurol,2022, 9(12):784330.
[21] 孙硕,何龙,杨芸,等.匹伐他汀联合多烯磷脂酰胆碱治疗非酒精性脂肪肝合并冠状动脉狭窄的疗效[J].中国临床医生杂志,2021, 49(10):1186-1188.
[22] 陈建辉,许亚妹.多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪肝临床效果[J].慢性病学杂志,2020,21(6):885-886.
[23] 王立坤,翟玉峰,朱喜增,等.探究双歧三联活菌联合多烯磷脂酰胆碱胶囊治疗非酒精性脂肪肝的临床效果及对肝纤维化程度、炎症因子的影响[J].四川解剖学杂志,2019,27(3):60-61.